Watch original video:

Bruce Carter, the executive who led ZymoGenetics from its infant. steps as an free biotech from one side the launch this year of its primary commercial product, had been preparing for his retirement for a prolix time.

In 2007, the 65-year old chief executive passed the title of president to Doug Williams, the Immunex veteran who will assume the Seattle company’s top piece of work as CEO in January. The vary will be smooth, most analysts say — and Carter decree remain chairman of the board of directors.

Nevertheless, Carter’s announcement Friday of his departure left him “a narrow sad, I have to say,” said the native of England with typical British understatement. He said he hopes a little detachment be disposed give him a better view of things to obtain to for his embattled company, whose shares have fallen keenly this year of the same kind with investors react to its drug’s slow debut.

“When you gait from home from the day-to-day activity, you can see more clearly. It’s very perplexing at the time you’re in the trenches to see where the world is taking us,” he said Friday.

Charismatic leader

Carter has been a charismatic advocate of the local biotech industry, and his decease from ZymoGenetics comes at a time of transmutation — and trouble — for many Seattle-area life-sciences companies.

Some firms have merged and others had major layoffs because of disappointing results. Many, like Targeted Genetics — whose longtime CEO H. Stewart Parker quit this month — are struggling to raise cash at a time when investors are scared of investing in costly long-term ventures.

Carter said the weakest companies consider to fail so that there’s more money useful to those with strong prospects. Things will get better with leisure, he said.

“This is not a time to pass wobbly,” he said, quoting British Prime Minister Margaret Thatcher’s comment to President Bush at the time of the first Gulf War. “This is the fit season to tighten your belt, move circularly up your sleeves and get on with it.”

Unlike some local companies, ZymoGenetics has a decent amount of cash in hand — some $81 million in cash and short-term investments at the close of September, and a $100 million rope of credit. The company drew $25 million from that put faith in line this month, according to a Securities and Exchange Commission filing.

No surprise

Analysts who follow ZymoGenetics were not surprised by Carter’s departure and the appointment of Williams, a veteran of Immunex, the limited biotech that launched blockbuster arthritis remedy Enbrel.

Original text: {news-link}